Thursday, October 20, 2016

Razadyne


See also: Generic Razadyne ER


Razadyne is a brand name of galantamine, approved by the FDA in the following formulation(s):


RAZADYNE (galantamine hydrobromide - solution; oral)



  • Manufacturer: JANSSEN PHARMS

    Approval date: June 22, 2001

    Strength(s): 4MG/ML [RLD][AA]

RAZADYNE (galantamine hydrobromide - tablet; oral)



  • Manufacturer: JANSSEN PHARMS

    Approval date: February 28, 2001

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [RLD][AB], EQ 8MG BASE [AB]

Has a generic version of Razadyne been approved?


A generic version of Razadyne has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Razadyne and have been approved by the FDA:


galantamine hydrobromide solution; oral



  • Manufacturer: ROXANE

    Approval date: January 30, 2009

    Strength(s): 4MG/ML [AA]

galantamine hydrobromide tablet; oral



  • Manufacturer: APOTEX INC

    Approval date: September 27, 2011

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: AUROBINDO PHARMA LTD

    Approval date: March 29, 2011

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: BARR

    Approval date: August 28, 2008

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: DR REDDYS LABS LTD

    Approval date: September 11, 2008

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: August 28, 2008

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: May 29, 2009

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: ROXANE

    Approval date: February 11, 2009

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: SANDOZ

    Approval date: June 22, 2009

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: TEVA PHARMS

    Approval date: July 9, 2009

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]


  • Manufacturer: ZYDUS PHARMS USA INC

    Approval date: February 17, 2011

    Strength(s): EQ 12MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Razadyne. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Fast-dissolving galanthamine hydrobromide tablet
    Patent 6,099,863
    Issued: August 8, 2000
    Inventor(s): Gilis; Paul Marie Victor & De Conde; Valentin Florent Victor
    Assignee(s): Janssen Pharmaceutica N.V.
    The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.
    Patent expiration dates:

    • June 6, 2017




  • Fast-dissolving galanthamine hydrobromide tablet
    Patent 6,358,527
    Issued: March 19, 2002
    Inventor(s): Paul Marie Victor; Gilis & Valentin Florent Victor; De Condé
    Assignee(s): Janssen Pharmaceutica N.V.
    The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.
    Patent expiration dates:

    • June 6, 2017
      ✓ 
      Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA
      ✓ 
      Drug product



See also...

  • Razadyne Consumer Information (Wolters Kluwer)
  • Razadyne Solution Consumer Information (Wolters Kluwer)
  • Razadyne Consumer Information (Cerner Multum)
  • Razadyne Advanced Consumer Information (Micromedex)
  • Razadyne IR Advanced Consumer Information (Micromedex)
  • Razadyne AHFS DI Monographs (ASHP)
  • Galantamine Consumer Information (Wolters Kluwer)
  • Galantamine Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Galantamine Solution Consumer Information (Wolters Kluwer)
  • Galantamine Consumer Information (Cerner Multum)
  • Galantamine Advanced Consumer Information (Micromedex)
  • Galantamine Hydrobromide AHFS DI Monographs (ASHP)

No comments:

Post a Comment